INmune Bio
INMB
83 hedge funds and large institutions have $48.1M invested in INmune Bio in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 8 closing their positions.
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more call options, than puts
Call options by funds: $3.07M | Put options by funds: $1.54M
14% more funds holding
Funds holding: 73 → 83 (+10)
14% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 22
6% less capital inflows, than outflows
Capital inflows: $5.49M | Capital outflows: $5.82M
1.65% less ownership
Funds ownership: 28.54% → 26.89% (-1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$702K |
| 2 |
GatePass Capital
Independence,
Ohio
|
+$635K |
| 3 |
Waratah Capital Advisors
Toronto,
Ontario, Canada
|
+$427K |
| 4 |
Praetorian PR
Rincon,
Puerto Rico
|
+$419K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$392K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$868K |
| 2 |
Raymond James Financial
St Petersburg,
Florida
|
-$743K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$570K |
| 4 |
Morgan Stanley
New York
|
-$561K |
| 5 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$486K |
INMB Hedge Fund Activity: Q1 2025 in Review
83 of the 7,486 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q1 2025, worth a combined $48.1M — up 63% from $29.5M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new INMB positions and 8 closed out — a net gain of 10 holders — while 25 added to existing stakes and 22 trimmed.
The largest buyer was Vanguard Group, adding an estimated $702K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $868K sold.
- 83 institutional investors held INmune Bio (INMB) as of Q1 2025, up from 73 in Q4 2024.
- Funds reported $48.1M of INmune Bio stock for Q1 2025, up 63% quarter-over-quarter.
- 18 funds opened new INmune Bio positions in Q1 2025 and 8 closed out, a net change of +10 holders.
- The largest INmune Bio buyer in Q1 2025 was Vanguard Group, an estimated $702K added.
- The largest INmune Bio seller in Q1 2025 was Renaissance Technologies, an estimated $868K sold.
Based on aggregated 13F filings for Q1 2025.